2 Result: Arcellx
Arcellx's IND Clinical Hold and Rhythm Pharma's Breakthrough: Weight Loss in HyOb Patients
June 20th, 2023
Arcellx, Inc. (Nasdaq: ACLX) said that its CART-ddBCMA investigational new drug (IND) for the treatment of relapsed or refractory multiple myeloma (rrMM) has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). The cl. Read more
Initiated with a Buy: Arcellx, Pliant Therapeutics, Tarsus Pharmaceuticals, Varonis Systems
May 18th, 2023
Several companies have recently received initiations with Buy ratings from prominent financial institutions, indicating positive outlooks for their future performance. Arcellx, Inc. (Nasdaq: ACLX) has been initiated with a Buy rating and a price t. Read more
Want To Find Some News?
News By Industries
Recent Post
-
December 05th, 2025
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025
Member Login